Custom-Made cancer vaccine shows promise in early trial
NCT ID NCT05071846
First seen Apr 24, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This early-phase study tests a personalized immunotherapy called MVX-ONCO-2 in 6 adults with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The main goal is to check safety and tolerability, while also looking for any signs that the tumor shrinks or stops growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpitaux Universitaires de Genève
Geneva, Switzerland
Conditions
Explore the condition pages connected to this study.